{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:02:51Z","timestamp":1787029371035,"version":"build-2736575974"},"reference-count":190,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cell-mediated drug delivery systems represent a promising frontier in dermatologic therapy by offering enhanced targeting precision, prolonged drug release, and reduced systemic toxicity. These systems leverage the intrinsic properties of immune cells, stem cells, and skin-resident cells to migrate toward inflamed or diseased skin and deliver therapeutic agents in a controlled and biocompatible manner. This review explores the mechanistic foundations of cell-mediated delivery, including chemotaxis, phagocytosis, and immune modulation, and examines current applications in inflammatory skin diseases such as atopic dermatitis and psoriasis, cutaneous malignancies such as melanoma and cutaneous T-cell lymphoma, and chronic wound healing. Engineering approaches such as cell surface modification, exosome loading, and integration with gene editing technologies are also discussed. Finally, we highlight translational challenges related to immunogenicity, manufacturing scalability, and regulatory considerations, and propose future directions for clinical adoption in dermatology. This review provides a comprehensive overview of the current landscape and outlines the potential for cell-based delivery systems to transform the treatment of chronic and refractory skin diseases.<\/jats:p>","DOI":"10.3390\/pharmaceutics17111438","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:56:45Z","timestamp":1762513005000},"page":"1438","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in Cell-Mediated Drug Delivery for Dermatologic Diseases: Mechanisms and Current Applications"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5200-541X","authenticated-orcid":false,"given":"Lara","family":"Shqair","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyla","family":"Draw","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Louisville School of Medicine, Louisville, KY 40202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0911-0929","authenticated-orcid":false,"given":"Tala","family":"Maya","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Louisville School of Medicine, Louisville, KY 40202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT 06511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Akbarialiabad","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Utah, Salt Lake City, UT 84103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1128-9626","authenticated-orcid":false,"given":"Todd","family":"Schlesinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-6505","authenticated-orcid":false,"given":"Giovanni","family":"Damiani","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Milan, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ghannoum","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-0584","authenticated-orcid":false,"given":"Ayman","family":"Grada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_2","first-page":"100281","article-title":"Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles","volume":"8","year":"2024","journal-title":"Int. J. Pharm. X"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e17488","DOI":"10.1016\/j.heliyon.2023.e17488","article-title":"Advances in drug delivery systems, challenges and future directions","volume":"9","author":"Ezike","year":"2023","journal-title":"Heliyon"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Li, J., Wang, Q., Xia, G., Adilijiang, N., Li, Y., Hou, Z., Fan, Z., and Li, J. (2023). Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15092233"},{"key":"ref_5","unstructured":"Yousef, H., Alhajj, M., Fakoya, A.O., Okpaleke, O., Khanna, S., and Sharma, S. (2025, September 27). Anatomy, Skin (Integument), Epidermis. [Updated 8 June 2024], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470464."},{"key":"ref_6","unstructured":"Lopez-Ojeda, W., Pandey, A., Alhajj, M., and Oakley, A.M. (2025, September 27). Anatomy, Skin (Integument) [Updated 17 October 2022], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441980."},{"key":"ref_7","unstructured":"Brown, T.M., and Krishnamurthy, K. (2025, September 27). Histology, Dermis. [Updated 14 November 2022], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535346."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nguyen, A.V., and Soulika, A.M. (2019). The Dynamics of the Skin\u2019s Immune System. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081811"},{"key":"ref_9","first-page":"200","article-title":"Common skin diseases","volume":"13","author":"Bezie","year":"2005","journal-title":"Int. Dev."},{"key":"ref_10","unstructured":"Kumar, P., and Clark, M. (2002). Skin disease. Clinical Medicine, W.B. Saunders. [5th ed.]."},{"key":"ref_11","unstructured":"Kazandjieva, J., and Tsankov, N. (2022). Unmet medical needs in chronic, non-communicable inflammatory skin diseases. Front. Med., 9."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhao, L., Chen, J., Bai, B., Song, G., Zhang, J., Yu, H., Huang, S., Wang, Z., and Lu, G. (2024). Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1333986"},{"key":"ref_13","first-page":"337","article-title":"Topical corticosteroids: Choice and application","volume":"103","author":"Stacey","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/CMR.00112-16","article-title":"Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns","volume":"30","author":"Williamson","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12943-023-01854-3","article-title":"Skin cancer: Understanding the journey of transformation from conventional to advanced treatment approaches","volume":"22","author":"Hasan","year":"2023","journal-title":"Mol. Cancer."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, D., Chen, M., Li, W., Xu, X., and Li, Q. (2025). Global burden of viral skin diseases from 1990 to 2021, A systematic analysis for the global burden of disease study 2021. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1464372"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1145513","DOI":"10.3389\/fpubh.2023.1145513","article-title":"The burden of skin and subcutaneous diseases: Findings from the Global Burden of Disease Study 2019","volume":"11","author":"Yakupu","year":"2023","journal-title":"Front Public Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jaad.2016.12.043","article-title":"The burden of skin disease in the United States","volume":"76","author":"Lim","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjd.18798","article-title":"A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis","volume":"183","author":"Villacorta","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/jid.2011.357","article-title":"The contribution of health services research to improved dermatologic care","volume":"132 Pt 2","author":"Chren","year":"2012","journal-title":"J Investig. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.7150\/thno.69999","article-title":"Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment","volume":"12","author":"Qu","year":"2022","journal-title":"Theranostics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2034890","DOI":"10.1001\/jamanetworkopen.2020.34890","article-title":"Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019","volume":"4","author":"Ballreich","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/17425247.2021.1823964","article-title":"Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases","volume":"18","author":"Korkmaz","year":"2021","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sanz-Nogu\u00e9s, C., and O\u2019Brien, T. (2021). Current good manufacturing practice considerations for mesenchymal stromal cells as therapeutic agents. Biomater. Biosyst., 2.","DOI":"10.1016\/j.bbiosy.2021.100018"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gorzelanny, C., Mess, C., Schneider, S.W., Huck, V., and Brandner, J.M. (2020). Skin Barriers in Dermal Drug Delivery: Which Barriers Have to Be Overcome and How Can We Measure Them?. Pharmaceutics., 12.","DOI":"10.3390\/pharmaceutics12070684"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"19145","DOI":"10.1021\/acsomega.2c08016","article-title":"New Insights in Topical Drug Delivery for Skin Disorders: From a Nanotechnological Perspective","volume":"8","author":"Raina","year":"2023","journal-title":"ACS Omega"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1007\/s13346-024-01614-w","article-title":"Drug delivery to and through the skin","volume":"14","author":"Guy","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Jeong, W.Y., Kwon, M., Choi, H.E., and Kim, K.S. (2021). Recent advances in transdermal drug delivery systems: A review. Biomater. Res., 25.","DOI":"10.1186\/s40824-021-00226-6"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bcp.12128","article-title":"Trials and tribulations of skin iontophoresis in therapeutics","volume":"77","author":"Roustit","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Aldawood, F.K., Andar, A., and Desai, S. (2021). A Comprehensive Review of Microneedles: Types, Materials, Processes, Characterizations and Applications. Polymers, 13.","DOI":"10.3390\/polym13162815"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Brito, S., Baek, M., and Bin, B.H. (2024). Skin Structure, Physiology, and Pathology in Topical and Transdermal Drug Delivery. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16111403"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e08938","DOI":"10.1016\/j.heliyon.2022.e08938","article-title":"Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery","volume":"8","author":"Souto","year":"2022","journal-title":"Heliyon"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Azman, M., Sabri, A.H., Anjani, Q.K., Mustaffa, M.F., and Hamid, K.A. (2022). Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery. Pharmaceuticals, 15.","DOI":"10.3390\/ph15080975"},{"key":"ref_34","first-page":"55","article-title":"Review on Novel Oral Therapies for Psoriasis","volume":"14","author":"Marushchak","year":"2021","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kulchar, R.J., Singh, R., Ding, S., Alexander, E., Leong, K.W., and Daniell, H. (2023). Delivery of biologics: Topical administration. Biomaterials., 302.","DOI":"10.1016\/j.biomaterials.2023.122312"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4103\/JCAS.JCAS_109_20","article-title":"Intralesional agents in dermatology: Pros and cons","volume":"14","author":"Sakhiya","year":"2021","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"ref_38","first-page":"e69764","article-title":"Current insights on treatment adherence in prevalent dermatological conditions and strategies to optimize adherence rates","volume":"16","author":"Radu","year":"2024","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jdcr.2021.08.022","article-title":"Successful treatment of corticosteroid-induced cutaneous atrophy and dyspigmentation with intralesional saline in the setting of keloids","volume":"16","author":"Dhinsa","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Telaprolu, K.C., Grice, J.E., Mohammed, Y.H., and Roberts, M.S. (2023). Human Skin Drug Metabolism: Relationships between Methyl Salicylate Metabolism and Esterase Activities in IVPT Skin Membranes. Metabolites, 13.","DOI":"10.3390\/metabo13080934"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1017\/erm.2024.5","article-title":"The role of the cytochrome P450 superfamily in the skin","volume":"26","author":"Chen","year":"2024","journal-title":"Expert. Rev. Mol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/17425247.2011.559457","article-title":"Cell-mediated drug delivery","volume":"8","author":"Batrakova","year":"2011","journal-title":"Expert. Opin. Drug Deliv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2400280","DOI":"10.1002\/smsc.202400280","article-title":"Transformative Impact of Nanocarrier-Mediated Drug Delivery: Overcoming Biological Barriers and Expanding Therapeutic Horizons","volume":"4","author":"Kim","year":"2024","journal-title":"Small Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Su, S., and MKang, P. (2020). Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090837"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/s41551-024-01230-6","article-title":"Cell-drug conjugates","volume":"8","author":"Wang","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nnano.2012.212","article-title":"Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions","volume":"8","author":"Parodi","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Li, H., Jin, K., Luo, M., Wang, X., Zhu, X., Liu, X., Jiang, T., Zhang, Q., Wang, S., and Pang, Z. (2019). Size dependency of circulation and biodistribution of biomimetic nanoparticles: Red blood cell membrane\u2013coated nanoparticles. Cells, 8.","DOI":"10.3390\/cells8080881"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"H105","DOI":"10.1002\/adma.201004074","article-title":"Cell-based drug delivery devices using phagocytosis-resistant backpacks","volume":"23","author":"Doshi","year":"2011","journal-title":"Adv. Mater."},{"key":"ref_50","first-page":"115385","article-title":"Cellular \u2018backpacks\u2019 for macrophage-mediated drug delivery in inflammation","volume":"207","author":"Northcutt","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: Why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Odeh-Couvertier, V.Y., Dwarshuis, N.J., Colonna, M.B., Levine, B.L., Edison, A.S., Kotanchek, T., Roy, K., and Torres-Garcia, W. (2022). Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform. Bioeng. Transl. Med., 7.","DOI":"10.1002\/btm2.10282"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Choudhury, M., Deans, A.J., Candland, D.R., and Deans, T.L. (2025). Advancing cell therapies with artificial intelligence and synthetic biology. Curr. Opin. Biomed. Eng., 34.","DOI":"10.1016\/j.cobme.2025.100580"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"20417314211028574","DOI":"10.1177\/20417314211028574","article-title":"3D bioprinting for skin tissue engineering: Current status and perspectives","volume":"12","author":"Weng","year":"2021","journal-title":"J. Tissue Eng."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2306470","DOI":"10.1002\/advs.202306470","article-title":"Diffusion-Based 3D Bioprinting Strategies","volume":"11","author":"Cai","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bo, T., Pascucci, E., Capuani, S., Campa-Carranza, J.N., Franco, L., Farina, M., Secco, J., Becchi, S., Cavazzana, R., and Joubert, A.L. (2024). 3D bioprinted mesenchymal stem cell laden scaffold enhances subcutaneous vascularization for delivery of cell therapy. Biomed. Microdevices, 26.","DOI":"10.1007\/s10544-024-00713-2"},{"key":"ref_57","first-page":"55","article-title":"Macrophage based drug delivery: Key challenges and strategies","volume":"38","author":"Guo","year":"2024","journal-title":"Bioact. Mater."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/IJN.S394389","article-title":"Cell-Based Drug Delivery Systems with Innate Homing Capability as a Novel Nanocarrier Platform","volume":"18","author":"Choi","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/JLB.4MIR0220-574RR","article-title":"Neutrophils at the crossroads of innate and adaptive immunity","volume":"108","author":"Rosales","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/s41590-024-02006-5","article-title":"The diverse roles of neutrophils from protection to pathogenesis","volume":"25","author":"Herro","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/imm.13394","article-title":"Unboxing dendritic cells: Tales of multi-faceted biology and function","volume":"164","author":"Giza","year":"2021","journal-title":"Immunology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1152\/physrev.00023.2001","article-title":"Dendritic cells: Immune regulators in health and disease","volume":"82","author":"Lipscomb","year":"2002","journal-title":"Physiol. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chen, L., Zhang, J., Huang, Y., Zhang, X., Zhang, G., Kong, S., Gao, J., Zhang, X., and Ding, B. (2025). Drug Delivery Systems Based on Dendritic-Cell-Derived Exosomes. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17030326"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Pulit-Penaloza, J., Esser, E.S., Vassilieva, E.V., Lee, J.W., Taherbhai, M.T., Pollack, B.P., Prausnitz, M.R., Compans, R.W., and Skountzou, I. (2014). A protective role of murine langerin+ cells in immune responses to cutaneous vaccination with microneedle patches. Sci. Rep., 4.","DOI":"10.1038\/srep06094"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1021\/nn304235j","article-title":"Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated PLGA nanoparticles induces efficient antitumor and antiviral immune responses","volume":"7","author":"Zaric","year":"2013","journal-title":"ACS Nano"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1039\/C4PY01394H","article-title":"Microneedle-assisted dendritic cell-targeted nanoparticles for transcutaneous DNA immunization","volume":"6","author":"Hu","year":"2015","journal-title":"Polym. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1080\/21645515.2016.1171440","article-title":"The success of microneedle-mediated vaccine delivery into skin","volume":"12","author":"Marshall","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2014.10.007","article-title":"Stem cells as drug delivery methods: Application of stem cell secretome for regeneration","volume":"82\u201383","author":"Tran","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Huang, Y., Wu, Q., and Tam, P.K.H. (2022). Immunomodulatory Mechanisms of Mesenchymal Stem Cells and Their Potential Clinical Applications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231710023"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jaci.2024.06.013","article-title":"Phase 1\/2 trials of human bone marrow-derived clonal mesenchymal stem cells for treatment of adults with moderate to severe atopic dermatitis","volume":"154","author":"Seo","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/1346-8138.15928","article-title":"Long-term efficacy and safety of intravenous injection of clonal mesenchymal stem cells derived from bone marrow in five adults with moderate to severe atopic dermatitis","volume":"48","author":"Shin","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.2147\/JIR.S479444","article-title":"Therapeutic potential and mechanisms of mesenchymal stem cell and mesenchymal stem cell-derived extracellular vesicles in atopic dermatitis","volume":"17","author":"He","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s13287-025-04649-z","article-title":"Mesenchymal stem cell-derived extracellular vesicles exert Th1-mediated anti-inflammatory effects via miR-146a\/NF-\u03baB pathway: Comparison with dupilumab in a mouse model of atopic dermatitis","volume":"16","author":"Park","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Kim, S.W., Lim, K.M., Cho, S.G., Ryu, B., Kim, C.Y., Park, S.Y., Jang, K., Jung, J.H., Park, C., and Choi, C. (2024). Efficacy of allogeneic and xenogeneic exosomes for the treatment of canine atopic dermatitis: A pilot study. Animals, 14.","DOI":"10.3390\/ani14020282"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Cho, B.S., Kim, S.B., Kim, S., Rhee, B., Yoon, J., and Lee, J.W. (2023). Canine mesenchymal-stem-cell-derived extracellular vesicles attenuate atopic dermatitis. Animals, 13.","DOI":"10.3390\/ani13132215"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1002\/jcp.27775","article-title":"Induced pluripotent stem cell-derived extracellular vesicles: A novel approach for cell-free regenerative medicine","volume":"234","author":"Taheri","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/cmi.2013.62","article-title":"Induced pluripotent stem cell (iPSCs) and their application in immunotherapy","volume":"11","author":"Jiang","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-023-01873-0","article-title":"Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1073\/pnas.94.1.219","article-title":"Transgenic studies with a keratin promoter-driven growth hormone transgene: Prospects for gene therapy","volume":"94","author":"Wang","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1089\/104303400750035843","article-title":"Regulated cutaneous gene delivery: The skin as a bioreactor","volume":"11","author":"Cao","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1046\/j.1365-2230.2002.01101.x","article-title":"Direct injection of naked DNA and cytokine transgene expression: Implications for keratinocyte gene therapy","volume":"27","author":"Sawamura","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"ref_84","unstructured":"ClinicalTrials.gov (2025, September 27). Phase 3, Open-Label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). ClinicalTrials.gov Identifier: NCT04227106. Sponsored by Abeona Therapeutics, Inc. Last Updated 5 December 2022, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04227106."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Vecin, N.M., and Kirsner, R.S. (2023). Skin substitutes as treatment for chronic wounds: Current and future directions. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1154567"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nature05664","article-title":"Progress and opportunities for tissue-engineered skin","volume":"445","author":"MacNeil","year":"2007","journal-title":"Nature"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Perisic, T., Zhang, Z., Foehr, P., Hopfner, U., Klutz, K., Burgkart, R.H., Slobodianski, A., Goeldner, M., Machens, H.G., and Schilling, A.F. (2017). Biodegradable poly (lactic acid-co-glycolic acid) scaffolds as carriers for genetically-modified fibroblasts. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174860"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s13287-020-01929-8","article-title":"Shedding light on the role of keratinocyte-derived extracellular vesicles on skin-homing cells","volume":"11","author":"Nasiri","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_89","unstructured":"Kersten Compliance Services, LLC (2011). LAVIV\u00ae (azficel-T): Biologics License Application (BLA) STN 125348 Summary Report, Kersten Compliance Services, LLC. Available online: https:\/\/kerstencompliance.com\/sites\/default\/files\/resources\/laviv.pdf."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/dsu.12204","article-title":"Successful treatment of depressed, distensible acne scars using autologous fibroblasts: A multi-site, prospective, double-blind, placebo-controlled clinical trial","volume":"39","author":"Weiss","year":"2013","journal-title":"Dermatol. Surg."},{"key":"ref_91","first-page":"263","article-title":"Autologous cultured fibroblast injection for facial contour deformities: A prospective, placebo-controlled, phase III clinical trial","volume":"33","author":"Weiss","year":"2007","journal-title":"Dermatol. Surg."},{"key":"ref_92","unstructured":"US Food and Drug Administration (2025, September 26). LAVIV (azficel-T)\u2014BLA 125348, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/laviv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Getting to the site of inflammation: The leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/ni1309","article-title":"Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2","volume":"7","author":"Serbina","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nri3244","article-title":"Information processing during phagocytosis","volume":"12","author":"Underhill","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","article-title":"Extracellular vesicles for drug delivery","volume":"106 Pt A","author":"Vader","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biotechadv.2012.08.008","article-title":"Exosomes for drug delivery\u2014A novel application for the mesenchymal stem cell","volume":"31","author":"Lai","year":"2013","journal-title":"Biotechnol. Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.1093133","article-title":"Nanotubular highways for intercellular organelle transport","volume":"303","author":"Rustom","year":"2004","journal-title":"Science"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"114097","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.stem.2013.09.006","article-title":"Mesenchymal stromal cells: Sensors and switchers of inflammation","volume":"13","author":"Bernardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcyt.2015.10.011","article-title":"Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells","volume":"18","author":"Najar","year":"2016","journal-title":"Cytotherapy"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.2147\/IJN.S298159","article-title":"Recent advances in macrophage-mediated drug delivery systems","volume":"16","author":"Liang","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jconrel.2015.07.030","article-title":"Using exosomes, naturally-equipped nanocarriers, for drug delivery","volume":"219","author":"Batrakova","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"114394","DOI":"10.1016\/j.addr.2022.114394","article-title":"Cell-based drug delivery systems and their in vivo fate","volume":"187","author":"Yang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00259-014-2945-x","article-title":"[^89Zr]Oxinate4 for long-term in vivo cell tracking by positron emission tomography","volume":"42","author":"Charoenphun","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.2174\/1381612811319370003","article-title":"Recent advances in superparamagnetic iron oxide nanoparticles for cellular imaging and targeted therapy research","volume":"19","author":"Wang","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Shin, K.O., Ha, D.H., Kim, J.O., Crumrine, D.A., Meyer, J.M., Wakefield, J.S., Lee, Y., Kim, B., Kim, S., and Kim, H.K. (2020). Exosomes from Human Adipose Tissue-Derived Mesenchymal Stem Cells Promote Epidermal Barrier Repair by Inducing de Novo Synthesis of Ceramides in Atopic Dermatitis. Cells, 9.","DOI":"10.3390\/cells9030680"},{"key":"ref_112","first-page":"51","article-title":"Endocytosis and exocytosis of nanoparticles in mammalian cells","volume":"9","author":"Oh","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-201X.2003.01093.x","article-title":"Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research","volume":"177","author":"Gehl","year":"2003","journal-title":"Acta Physiol. Scand."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10717544.2016.1230903","article-title":"A novel strategy to achieve effective drug delivery: Exploit cells as carriers combined with nanoparticles","volume":"24","author":"Pang","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.nantod.2011.04.001","article-title":"Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials","volume":"6","author":"Stephan","year":"2011","journal-title":"Nano Today"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nm.2198","article-title":"Therapeutic cell engineering with surface-conjugated synthetic nanoparticles","volume":"16","author":"Stephan","year":"2010","journal-title":"Nat. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Susnik","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Milo\u0161evi\u0107, N., R\u00fctter, M., and David, A. (2022). Endothelial Cell Adhesion Molecules- (un)Attainable Targets for Nanomedicines. Front. Med. Technol., 4.","DOI":"10.3389\/fmedt.2022.846065"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Frigault","year":"2018","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"27066","DOI":"10.3402\/jev.v4.27066","article-title":"Biological properties of extracellular vesicles and their physiological functions","volume":"4","author":"Siljander","year":"2015","journal-title":"J. Extracell. Vesicles"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","article-title":"Communication by Extracellular Vesicles: Where We Are and Where We Need to Go","volume":"164","author":"Tkach","year":"2016","journal-title":"Cell"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/stem.2575","article-title":"Concise Review: MSC-Derived Exosomes for Cell-Free Therapy","volume":"35","author":"Phinney","year":"2017","journal-title":"Stem Cells"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","article-title":"Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy","volume":"207","author":"Haney","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.addr.2010.08.010","article-title":"Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery","volume":"62","author":"Porada","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13287-016-0303-6","article-title":"Mesenchymal stem cells and cutaneous wound healing: Novel methods to increase cell delivery and therapeutic efficacy","volume":"7","author":"Lee","year":"2016","journal-title":"Stem Cell Res. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Zhang, S., Liang, Y., Xia, M., Tian, X., Chen, Z., Lin, L., Liang, J., and Liu, Y. (2025). Serum exosomal microRNA profiling reveals a down-regulation of hsa-miR-124-3p in patients with severe acne. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1554811"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Wong, R.S.Y., Chua, K.H., Tan, E.W., and Goh, B.H. (2025). Therapeutic Potential of Mesenchymal Stem Cells in Psoriasis. Cell Biochem. Biophys., 1\u201315.","DOI":"10.1007\/s12013-025-01843-x"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"156699","DOI":"10.1016\/j.cyto.2024.156699","article-title":"The role of mesenchymal stem cells in the treatment and pathogenesis of psoriasis","volume":"182","author":"Chen","year":"2024","journal-title":"Cytokine"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3523642","DOI":"10.1155\/2018\/3523642","article-title":"Involvement of M1 Macrophage Polarization in Endosomal Toll-Like Receptors Activated Psoriatic Inflammation","volume":"2018","author":"Lu","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Liu, J.M., Jin, Q.X., Fujimoto, M., Li, F.F., Jin, L.B., Yu, R., Yan, G.H., Zhu, L.H., Meng, F.P., and Zhang, Q.G. (2021). Dihydroartemisinin alleviates imiquimod-induced psoriasis-like skin lesion in mice involving modulation of IL-23\/Th17 axis. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.704481"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Zhang, W., Lin, J., Shi, P., Su, D., Cheng, X., Yi, W., Yan, J., Chen, H., and Cheng, F. (2022). Small extracellular vesicles derived from MSCs have immunomodulatory effects to enhance delivery of ASO-210 for psoriasis treatment. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.842813"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Luliano, M., Grimaldi, L., Rosa, P., Scibetta, S., Bernardini, N., Proietti, I., Tolino, E., Skroza, N., Potenza, C., and Mangino, G. (2024). Extracellular vesicles in psoriasis: From pathogenesis to possible roles in therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1360618"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/sctm.16-0363","article-title":"Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: Endorsement of macrophage polarization","volume":"6","author":"Reverberi","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Ubanako, P., Mirza, S., Ruff, P., and Penny, C. (2024). Exosome-mediated delivery of siRNA molecules in cancer therapy: Triumphs and challenges. Front. Mol. Biosci., 11.","DOI":"10.3389\/fmolb.2024.1447953"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Ha, D.H., Kim, H., Lee, J., Kwon, H.H., Park, G.H., Yang, S.H., Jung, J.Y., Choi, H., Lee, J.H., and Sung, S. (2020). Mesenchymal stem\/stromal cell-derived exosomes for immunomodulatory therapeutics and skin regeneration. Cells, 9.","DOI":"10.3390\/cells9051157"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00441-022-03697-8","article-title":"Secretome of human umbilical cord mesenchymal stem cell maintains skin homeostasis by regulating multiple skin physiological function","volume":"391","author":"Wang","year":"2023","journal-title":"Cell Tissue Res."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Yang, J., Xiao, M., Ma, K., Li, H., Ran, M., Yang, S., Yang, Y., Fu, X., and Yang, S. (2023). Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: Atopic dermatitis and psoriasis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1092668"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1126\/science.abp9563","article-title":"Engineered skin bacteria induce antitumor T cell responses against melanoma","volume":"380","author":"Chen","year":"2023","journal-title":"Science"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e120608","DOI":"10.1172\/jci.insight.120608","article-title":"First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis","volume":"3","author":"Myles","year":"2018","journal-title":"JCI Insight"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41591-021-01256-2","article-title":"Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial","volume":"27","author":"Nakatsuji","year":"2021","journal-title":"Nat. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamadermatol.2021.1311","article-title":"Use of autologous bacteriotherapy to treat Staphylococcus aureus in patients with atopic dermatitis: A randomized double-blind clinical trial","volume":"157","author":"Nakatsuji","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_144","unstructured":"ClinicalTrials.gov (2025, September 27). Targeted Microbiome Transplant in Atopic Dermatitis. ClinicalTrials.gov Identifier: NCT03151148, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03151148."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-025-00957-5","article-title":"Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma","volume":"26","author":"Tsai","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Mehta, A., Motavaf, M., Nebo, I., Luyten, S., Osei-Opare, K.D., and Gru, A.A. (2025). Advancements in melanoma treatment: A review of PD-1 inhibitors, T-VEC, mRNA vaccines, and tumor-infiltrating lymphocyte therapy in an evolving landscape of immunotherapy. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041200"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"eRW0935","DOI":"10.31744\/einstein_journal\/2024RW0935","article-title":"Efficacy of treatment with tumor-infiltrating lymphocytes as adoptive cell therapy: An integrative review","volume":"22","author":"Vieira","year":"2024","journal-title":"Einstein"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e006822","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Babajani, A., Soltani, P., Jamshidi, E., Farjoo, M.H., and Niknejad, H. (2020). Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer. Front. Bioeng. Biotechnol., 8.","DOI":"10.3389\/fbioe.2020.00748"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Zhang, T., Jou, T.H., Hsin, J., Wang, Z., Huang, K., Ye, J., Yin, H., and Xing, Y. (2023). Talimogene laherparepvec (T-VEC): A review of the recent advances in cancer therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031098"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e006270","DOI":"10.1136\/jitc-2022-006270","article-title":"Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial","volume":"11","author":"Chesney","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Natarelli, N., Gahoonia, N., and Sivamani, R.K. (2023). Bacteriophages and the microbiome in dermatology: The role of the phageome and a potential therapeutic strategy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032695"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1002\/ski2.93","article-title":"Development of a topical bacteriophage gel targeting Cutibacterium acnes for acne-prone skin and results of a phase 1 cosmetic randomized clinical trial","volume":"2","author":"Golembo","year":"2022","journal-title":"Skin. Health Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaad.2024.08.027","article-title":"Effective and durable repigmentation for stable vitiligo: A randomized within-subject controlled trial assessing treatment with autologous skin cell suspension transplantation","volume":"91","author":"Hamzavi","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13287-019-1364-0","article-title":"Differentiation of adipose-derived stem cells to functional CD105neg CD73low melanocyte precursors guided by defined culture condition","volume":"10","author":"Zavala","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1590\/abd1806-4841.20132054","article-title":"Non-cultured melanocyte\/keratinocyte transplantation for the treatment of stable vitiligo on the face: Report of two cases","volume":"88","author":"Ramos","year":"2013","journal-title":"An. Bras. Dermatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2147\/CCID.S485421","article-title":"Sustained Repigmentation in Vitiligo and Leukodermas Using Melanocyte\u2013Keratinocyte Transplantation: 7 Years of Data","volume":"17","author":"Nuntawisuttiwong","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaad.2017.01.056","article-title":"Long-term follow-up of patients undergoing autologous noncultured melanocyte-keratinocyte transplantation for vitiligo and other leukodermas","volume":"77","author":"Griffith","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Nowak-Liduk, A., Kitala, D., Ocha\u0142a-Gierek, G., \u0141abu\u015b, W., Bergler-Czop, B., Pietrauszka, K., Niemiec, P., Szyluk, K., and Gierek, M. (2023). Hidradenitis suppurativa: An interdisciplinary problem in dermatology, gynecology, and surgery\u2014Pathogenesis, comorbidities, and current treatments. Life, 13.","DOI":"10.3390\/life13091895"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40257-024-00871-2","article-title":"Adherence to hidradenitis suppurativa treatment","volume":"25","author":"Dagenet","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/ajh.26299","article-title":"Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management","volume":"96","author":"Hristov","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Knoedler, S., Broichhausen, S., Guo, R., Dai, R., Knoedler, L., Kauke-Navarro, M., Diatta, F., Pomahac, B., Machens, H.G., and Jiang, D. (2023). Fibroblasts-the cellular choreographers of wound healing. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1233800"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Guillamat-Prats, R. (2021). The Role of MSC in Wound Healing, Scarring and Regeneration. Cells, 10.","DOI":"10.3390\/cells10071729"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13287-017-0644-9","article-title":"Multipotent stromal cells\/mesenchymal stem cells and fibroblasts combine to minimize skin hypertrophic scarring","volume":"8","author":"Yates","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Jo, C., Choi, Y.J., and Lee, T.J. (2025). Therapeutic Potential of Stem Cell-Derived Exosomes in Skin Wound Healing. Biomimetics, 10.","DOI":"10.3390\/biomimetics10080546"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/01.PRS.0000142415.57470.DF","article-title":"Clinical application of fresh fibroblast allografts for the treatment of diabetic foot ulcers: A pilot study","volume":"114","author":"Han","year":"2004","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Manole, C.G., Soare, C., Ceafalan, L.C., and Voiculescu, V.M. (2023). Platelet-rich plasma in dermatology: New insights on the cellular mechanism of skin repair and regeneration. Life, 14.","DOI":"10.3390\/life14010040"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Vladulescu, D., Scurtu, L.G., Simionescu, A.A., Scurtu, F., Popescu, M.I., and Simionescu, O. (2023). Platelet-rich plasma (PRP) in dermatology: Cellular and molecular mechanisms of action. Biomedicines, 12.","DOI":"10.3390\/biomedicines12010007"},{"key":"ref_171","first-page":"100372","article-title":"Platelet-rich plasma-contained drug delivery systems to treat orthopedic injuries","volume":"10","author":"Liu","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.14597","article-title":"Granulocyte transfusions in the management of invasive fungal infections","volume":"177","author":"West","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1182\/blood-2015-05-645986","article-title":"Efficacy of transfusion with granulocytes from G-CSF\/dexamethasone-treated donors in neutropenic patients with infection","volume":"126","author":"Price","year":"2015","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Michelen, Y., Kantarjian, H.M., Ravandi, F., Pemmaraju, N., Kadia, T.M., Konopleva, M., Verstovsek, S., Daver, N.G., Garcia-Manero, G., and Krause, H. (2019). Granulocyte transfusions in patients with skin and soft tissue infections and leukemia: Are they useful?. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.7022"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Mei, R., Wan, Z., Yang, C., Shen, X., Wang, R., Zhang, H., Yang, R., Li, J., Song, Y., and Su, H. (2024). Advances and clinical challenges of mesenchymal stem cell therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1421854"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"114827","DOI":"10.1016\/j.addr.2023.114827","article-title":"Myeloid cell-mediated drug delivery: From nanomedicine to cell therapy","volume":"197","author":"Zhang","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Santos, M.E., Garcia-Arranz, M., Andreu, E.J., Garc\u00eda-Hern\u00e1ndez, A.M., L\u00f3pez-Parra, M., Villar\u00f3n, E., Sep\u00falveda, P., Fern\u00e1ndez-Avil\u00e9s, F., Garc\u00eda-Olmo, D., and Prosper, F. (2022). Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.918565"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"114840","DOI":"10.1016\/j.addr.2023.114840","article-title":"Engineering cells for precision drug delivery: New advances, clinical translation, and emerging strategies","volume":"197","author":"Chao","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Agrawal, S., Vaidya, S., Patel, J., Jirvankar, P., and Gurjar, P. (2025). Challenges and pathways in regulating next-gen biological therapies. Curr. Pharm. Biotechnol.","DOI":"10.2174\/0113892010367028250411111549"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"105885","DOI":"10.1016\/j.yrtph.2025.105885","article-title":"Analysis of cellular and gene therapy product reviews in the United States","volume":"162","author":"Weng","year":"2025","journal-title":"Regul. Toxicol. Pharmacol. RTP"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1021\/acs.molpharmaceut.3c00162","article-title":"Knowledge Gaps in Generating Cell-Based Drug Delivery Systems and a Possible Meeting with Artificial Intelligence","volume":"20","author":"Mozafari","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/imr.13236","article-title":"Harnessing the power of artificial intelligence to advance cell therapy","volume":"320","author":"Capponi","year":"2023","journal-title":"Immunol. Rev."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"114072","DOI":"10.1016\/j.jconrel.2025.114072","article-title":"Biomaterial scaffolds for therapeutic immune cell engineering and delivery","volume":"386","author":"Wolter","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e1902005","DOI":"10.1002\/adma.201902005","article-title":"Biomaterials for Personalized Cell Therapy","volume":"32","author":"Facklam","year":"2020","journal-title":"Adv. Mater."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41587-021-00942-3","article-title":"The need for global access to biomedical innovations during pandemics","volume":"39","author":"Gupta","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e20230903","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Khericha","year":"2024","journal-title":"J. Exp. Med."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Lonez, C., and Breman, E. (2024). Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells, 13.","DOI":"10.3390\/cells13020146"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/jrms.jrms_610_23","article-title":"Ethical guidelines for human research on children and adolescents: A narrative review study","volume":"29","author":"Askari","year":"2024","journal-title":"J. Res. Med. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1038\/s41467-020-20096-1","article-title":"Patient and public perspectives on cell and gene therapies: A systematic review","volume":"11","author":"Aiyegbusi","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1438\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:07:57Z","timestamp":1762513677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":190,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pharmaceutics17111438"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17111438","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}